General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products under the oh care brand. Further, the company serves its diagnostic solutions through clinics and laboratories. General Biologicals Corporation was founded in 1984 and is headquartered in Hsinchu City, Taiwan.
Frequently asked questions
What sector does General Biologicals Corporation (4117) operate in?
General Biologicals Corporation belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is General Biologicals Corporation (4117) current stock price?
As of the latest data, General Biologicals Corporation stock price is NT$10.30, with a previous close of NT$10.30.
What is General Biologicals Corporation (4117) current market capitalization?
General Biologicals Corporation market cap is approximately 729.49 million.
What is General Biologicals Corporation (4117) Earnings Per Share (EPS)?
The trailing EPS is NT$7.44.
What is General Biologicals Corporation (4117) Price-to-Earnings (P/E) ratio?
General Biologicals Corporation current P/E ratio is 1.38.
Does General Biologicals Corporation (4117) pay dividends?
No. General Biologicals Corporation does not pay a dividend.
What is General Biologicals Corporation (4117) beta (volatility) score?
General Biologicals Corporation has a beta of 0.613, indicating lower volatility than the overall market.
